GlassScriptPhysician profile
Derek Michael Reed
NPI 1306896147
$4,689.23
in general payments reported to CMS, 2019-2025
43 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.92 · 2020: $308 · 2021: $196 · 2022: $417 · 2023: $1,248 · 2024: $1,361 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,753.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $815.65 | 2020-2025 | |
| Pfizer INC. | $486.77 | 2020-2025 | |
| Lilly USA, LLC | $475.11 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $417.20 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $274.00 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $213.46 | 2020-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $188.35 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $160.88 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.02 | 2023-2025 | Jardiance, Synjardy, Glyxambi |
| Amgen INC. | $113.08 | 2022-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.27 | 2020-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $93.87 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Otsuka America Pharmaceutical, INC. | $92.53 | 2023-2025 | Rexulti |
| Dexcom, INC. | $86.30 | 2023-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $85.04 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.